3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
28
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Disease
1
Carcinoma
1
Calcinosis
1
Brain Neoplasms
1
Interventions
Mammography
4
Magnetic Resonance Spectroscopy
3
pembrolizumab
1
Vertical Dimension
1
Therapeutics
1
TKM-080301
1
Surveys and Questionnaires
1
Sensitivity Training Groups
1
Self-Management
1
Referral and Consultation
1
Quality of Life
1
Professional Autonomy
1
Patient Positioning
1
Paclitaxel
1
Methylene Blue
1
Mass Screening
1
Magnetic Resonance Imaging
1
Interviews as Topic
1
Interleukin-15
1
Gemcitabine
1
Exercise
1
Drug Delivery Systems
1
Doxorubicin
1
Counseling
1
Blood Specimen Collection
1
Biopsy
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Magnetic Resonance Imaging
×
Breast
×
Clear all
NCT06629896
2026-05-07
CEM
Azienda USL Reggio Emilia - IRCCS
Phase NA
Recruiting
2,200 enrolled